Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration.

The present study was designed to analyse the cytotoxic effect of cisplatin in vitro as a function of various exposure times (up to 120 h), keeping constant the parameter C x T (product of the drug concentration per time). Intracellular drug concentrations were measured in parallel following analysis of cisplatin influx and efflux characteristics. A head and neck cancer cell line was selected to represent the spectrum of cisplatin antitumour activity. The IC50 values (micrograms/ml) for 1, 2, 11 and 121 h were, respectively 4.51, 2.73, 0.27 and 0.151. Reduction of the IC50 was clearly not linearly related to prolongation of the cisplatin exposure time. The kinetics of cisplatin incorporation into CAL 27 cells was investigated as a function of different cisplatin concentrations. A plateau was reached after 16 h of contact. For the extracellular cisplatin concentrations of 1, 2.5, 5 and 10 micrograms/ml, the average intracellular Pt concentrations at the plateau were, respectively (ng/10(6) cells): [mean (S.D.)] 12.8 (0.98), 31.11 (5.12), 71.38 (6.03) and 136.7 (16.5). Intracellular Pt concentrations were linearly related to the extracellular drug concentration (r = 0.99). The drug left the cells following a two-slope kinetics pattern with an alpha half-life of 1.29 h and a beta half-life of 94.4 h. The cytotoxic effect for a given C x T clearly differed for the different cisplatin exposure times. The longest exposure time (121 h) gave the least pronounced cytotoxicity. The intracellular Pt concentrations were linearly related to the C x T values. Cisplatin levels were much lower after the 121 h exposure. These data may prove valuable in establishing a rationale which can aid in selection of optimal modes of clinical cisplatin administration.

[1]  J. Whitehouse,et al.  Cis-platinum: a new anticancer agent. , 1979, British medical journal.

[2]  N. Vogelzang Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Olshen,et al.  Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.

[4]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[5]  B. Brown,et al.  The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. , 1973, Cancer research.

[6]  B. Barlogie,et al.  Effects of cis-dichlorodiammineplatinum(II) on human colon carcinoma cells in vitro. , 1979, Cancer research.

[7]  D. V. Von Hoff,et al.  Cis-diamminedichloroplatinum (II). A new anticancer drug. , 1977, Annals of internal medicine.

[8]  B. Hill,et al.  Concentration and time‐dependent inter‐relationships for antitumour drug cytotoxicities against tumour cells in vitro , 1983, International journal of cancer.

[9]  M. Straus,et al.  Effects of pulse and continuous intravenous infusion of cis-diamminedichloroplatinum on L1210 leukemia in vivo. , 1981, Cancer research.

[10]  B. Hecquet,et al.  Uptake of platinum compounds in human tumors. In vitro study. , 1986, Bulletin du cancer.

[11]  L. Ferrari,et al.  Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. , 1986, Cancer treatment reports.

[12]  F. Petrucci,et al.  A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Eichholtz-Wirth,et al.  The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. , 1986, British Journal of Cancer.

[14]  M. Posner,et al.  Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. , 1988, Cancer research.

[15]  H. Pinedo,et al.  Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. , 1982, European journal of cancer & clinical oncology.

[16]  C. Anderson,et al.  Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Einhorn,et al.  Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Rozencweig,et al.  Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM40 in a human myeloid clonogenic assay. , 1988, European journal of cancer & clinical oncology.

[19]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin , 1986, Clinical pharmacology and therapeutics.